- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00126620
Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
A Phase I Study of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib; Tarceva) in Advanced Solid Tumors
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib and erlotinib in treating patients with metastatic or unresectable solid tumors.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
OBJECTIVES:
Primary
- Determine the maximum tolerated dose and recommended phase II dose of sorafenib and erlotinib in patients with metastatic or unresectable solid tumors.
Secondary
- Determine the optimal biologically effective dose of this regimen that will lead to hypophosphorylation of epidermal growth factor receptor (EGFR), ERK, Akt, and vascular endothelial growth factor receptor (VEGFR), and inhibition of angiogenesis and apoptosis with tolerable toxicity in these patients.
- Correlate the pharmacokinetic profiles of this regimen with toxicity and biological activity in these patients.
- Determine, preliminarily, the antitumor activity of this regimen in these patients.
- Correlate phosphorylation status of EGFR, ERK, Akt, and VEGFR with antitumor activity of this regimen in these patients.
OUTLINE: This is a multicenter, open label, non-randomized, dose-escalation study.
Patients receive oral sorafenib alone once or twice daily on days -6 to 0*. Patients then receive oral sorafenib once or twice daily and oral erlotinib once daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Not considered part of course 1; considered a "run-in" period only.
Cohorts of 3-6 patients receive escalating doses of sorafenib and erlotinib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 10 patients are treated at the MTD.
After completion of study treatment, patients are followed at 4 weeks and then at least annually thereafter.
PROJECTED ACCRUAL: A total of 16-28 patients will be accrued for this study within 5-14 months.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8V 5C2
- Margaret and Charles Juravinski Cancer Centre
-
Toronto, Ontario, Kanada, M5G 2M9
- Princess Margaret Hospital
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
DISEASE CHARACTERISTICS:
Histologically confirmed solid tumor
- Metastatic or unresectable disease
- Standard curative or palliative measures do not exist OR are no longer effective
- Measurable disease by radiography (for patients treated at the maximum tolerated dose [MTD] only)
- Tumor accessible for serial biopsies (for patients treated at the MTD only)
- No known brain metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2 OR
- Karnofsky 60-100%
Life expectancy
- More than 12 weeks
Hematopoietic
- WBC ≥ 3,000/mm^3
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- No bleeding diathesis or coagulopathy
Hepatic
- Bilirubin normal
- AST and ALT ≤ 2.5 times ULN
- PT INR ≤ 1.5 unless on full-dose warfarin
Renal
- Creatinine normal OR
- Creatinine clearance ≥ 60 mL/min
Cardiovascular
- No uncontrolled hypertension (i.e., systolic blood pressure [BP] > 140 mm Hg or diastolic BP > 90 mm Hg despite medication)
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
Ophthalmic
No abnormalities of the cornea, including any of the following:
- Dry eye syndrome
- Sjögren's syndrome
- Congenital abnormalities (e.g., Fuch's dystrophy)
- Abnormal slit-lamp examination using a vital dye (e.g., fluorescein or Bengal-Rose)
- Abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production test)
Gastrointestinal
- No active peptic ulcer disease that would impair the ability to swallow pills
- No gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Willing to undergo serial biopsies, positron emission tomography, and CT scanning (for patients treated at the MTD only)
- No ongoing or active infection
- No significant traumatic injury within the past 3 weeks
- No history of allergic reaction to drugs of similar chemical or biological composition to study drugs
- No psychiatric illness or social situation that would preclude study compliance
- No other condition that would impair the ability to swallow pills
- No other uncontrolled illness
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No concurrent prophylactic hematopoietic colony-stimulating factors
Chemotherapy
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
Endocrine therapy
- Not specified
Radiotherapy
- More than 4 weeks since prior radiotherapy (except for low dose, non-myelosuppressive radiotherapy) and recovered
Surgery
- More than 3 weeks since prior major surgery
- No prior surgical procedure affecting absorption
Other
- No prior sorafenib or erlotinib
- No other prior agents targeting Raf, vascular endothelial growth factor (VEGF), VEGF receptor, or epidermal growth factor receptor
- No other concurrent investigational agents
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No concurrent enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital)
- No concurrent CYP3A4 inducers (e.g., rifampin or Hypericum perforatum [St. John's wort])
- No other concurrent anticancer therapy
- Concurrent prophylactic anticoagulation therapy (e.g., low-dose warfarin) allowed provided PT INR < 1.1 times upper limit of normal (ULN)
Concurrent full-dose anticoagulants (e.g., warfarin) with PT INR > 1.5 allowed provided both of the following criteria are met:
- Patient has an in range INR (between 2-3) while on a stable-dose of oral anti-coagulant OR a stable-dose of low molecular weight heparin
- No active bleeding OR pathological condition that would confer a high risk of bleeding (e.g., tumor involving a major vessel or known varices)
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Nerandomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: OSI-774 erlotinib) and Bay 43-9006 (Sorafenib)
Sorafenib administered alone for a 1-week run-in period, and then both drugs e given together continuously, with every 28 days considered as a cycle.
Three dose levels assessed.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Maximum tolerated dose and recommended phase II dose
Časové okno: 28 days
|
28 days
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Pharmacodynamic outcomes
Časové okno: Pre study and cycle 1
|
Pre study and cycle 1
|
Pharmacokinetic outcomes
Časové okno: Pre-study, cycle 1 and cycle 2
|
Pre-study, cycle 1 and cycle 2
|
Antitumor activity
Časové okno: Every 8 wks
|
Every 8 wks
|
Correlation of EGFR, AKT, ERK and VEGFR with antitumor activity
Časové okno: If responses or prolonged stable disease are observed
|
If responses or prolonged stable disease are observed
|
EGFR activating mutations, gene amplification status, EGFR intron 1 polymorphism if responses or prolonged disease stabilization are seen
Časové okno: If responses or prolonged stable disease are observed
|
If responses or prolonged stable disease are observed
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Vyšetřovatelé
- Studijní židle: Lillian L. Siu, MD, FRCPC, Princess Margaret Hospital, Canada
Publikace a užitečné odkazy
Obecné publikace
- Quintela-Fandino M, Le Tourneau C, Duran I, Chen EX, Wang L, Tsao M, Bandarchi-Chamkhaleh B, Pham NA, Do T, MacLean M, Nayyar R, Tusche MW, Metser U, Wright JJ, Mak TW, Siu LL. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Mol Cancer Ther. 2010 Mar;9(3):751-60. doi: 10.1158/1535-7163.MCT-09-0868. Epub 2010 Mar 2.
- Duran I, Hotte SJ, Hirte H, Chen EX, MacLean M, Turner S, Duan L, Pond GR, Lathia C, Walsh S, Wright JJ, Dancey J, Siu LL. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res. 2007 Aug 15;13(16):4849-57. doi: 10.1158/1078-0432.CCR-07-0382.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- PMH-PHL-042
- CDR0000437855 (Identifikátor registru: PDQ (Physician Data Query))
- NCI-7178
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na erlotinib hydrochlorid
-
M.D. Anderson Cancer CenterDokončenoPokročilá rakovinaSpojené státy
-
European Organisation for Research and Treatment...DokončenoRakovina vaječníků | Rakovina vejcovodů | Primární rakovina peritoneální dutinyFrancie, Španělsko, Holandsko, Austrálie, Spojené království, Itálie, Portugalsko, Rakousko
-
University of ChicagoNational Cancer Institute (NCI)DokončenoMaligní peritoneální mezoteliomSpojené státy
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)DokončenoRakovina hlavy a krkuŠpanělsko, Spojené státy
-
National Cancer Institute (NCI)NCIC Clinical Trials GroupDokončenoEndometriální rakovinaKanada
-
Southwest Oncology GroupNational Cancer Institute (NCI)DokončenoRakovina žaludku | Rakovina jícnuSpojené státy, Kanada
-
National Cancer Institute (NCI)DokončenoSpinocelulární karcinom děložního čípku | Recidivující rakovina děložního čípkuSpojené státy
-
University Health Network, TorontoNational Cancer Institute (NCI)DokončenoRakovina hlavy a krkuKanada
-
National Cancer Institute (NCI)DokončenoRakovina prsuSpojené státy
-
National Cancer Institute (NCI)DokončenoStádium IIIB nemalobuněčný karcinom plic | Recidivující nemalobuněčný karcinom plic | Stádium IV nemalobuněčného karcinomu plic | Spinocelulární rakovina plic | Adenokarcinom plic | Velkobuněčná rakovina plicSpojené státy